Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial
- Posted on September 22, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial
Sept 22 (Reuters) - Swiss drugmaker Roche said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15.5% of their body weight in a mid-stage trial. Roche is racing alongside large drugmakers, including AstraZeneca and Amgen, to break into the lucrative obesity drug market and challenge leaders
